VulnerabilityDeferred

CVE-2025-0416

Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023.

HIGH 8.9EPSS 0.22%

Does this matter?

High impact if exploited, but EPSS currently rates exploitation as unlikely (0.22%). Schedule it in the normal patch cycle and watch for a rise in EPSS or a public exploit.

Description

Local privilege escalation through insecure DCOM configuration in Valmet DNA versions prior to C2023. The DCOM object Valmet DNA Engineering has permissions that allow it to run commands as a user with the SeImpersonatePrivilege privilege. The SeImpersonatePrivilege privilege is a Windows permission that allows a process to impersonate another user. An attacker can use this vulnerability to escalate their privileges and take complete control of the system.

CVSS 4.0: 8.9 HIGHCVSS:4.0/AV:A/AC:L/AT:P/PR:L/UI:N/VC:H/VI:H/VA:H/SC:H/SI:H/SA:H/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/M
EPSS: 0.22% probability · 12th percentile
CISA KEV: Not listed
Weakness: CWE-250
Source: db4dfee8-a97e-4877-bfae-eba6d14a2166

References

https://www.valmet.com/about-us/about/research-and-development/vulnerabilityadvisories/cve-2025-0416/

Source: NVD record, EPSS from FIRST.org, KEV from CISA. Refreshed daily.